@article {7973,
	title = {Update on recommendations for assessing response from the Third International Workshop on Waldenstr{\"o}m{\textquoteright}s macroglobulinemia},
	journal = {Clinical Lymphoma and Myeloma},
	volume = {6},
	year = {2006},
	note = {Cited By :72Export Date: 21 February 2017},
	month = {2006},
	pages = {380 - 383},
	abstract = {This report by an international consensus panel updates current recommendations for defining clinical response in Waldenstr{\"o}m{\textquoteright}s macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.},
	keywords = {Bence Jones protein, Disease Progression, Immunoglobulin M, relapse},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646546982\&doi=10.3816\%2fCLM.2006.n.013\&partnerID=40\&md5=920bcccdea389b6d1b028bc52f996d1e},
	author = {Kimby, E. and Treon, S.P. and Anagnostopoulos, A. and Dimopoulos, M. and Garcia-Sanz, R. and Gertz, M.A. and Johnson, S. and Leblond, V. and Fermand, J.-P. and Maloney, D.G. and Merlini, G. and Morel, P. and Morra, E. and Nichols, G. and Ocio, E.M. and Owen, R. and Stone, M. and Blad{\'e}, J.}
}
